Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042384 (
vasculitis
)
20,525
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The protein C pathway is a primary regulator of blood coagulation and a critical component of the host response to inflammatory stimuli. The most recent member of this pathway is the
endothelial protein C receptor
(
EPCR
), a type I transmembrane protein with homology to CD1d/MHC class I proteins.
EPCR
accelerates formation of activated protein C, a potent anticoagulant and antiinflammatory agent. The current study demonstrates that soluble
EPCR
binds to PMA-activated neutrophils. Using affinity chromatography, binding studies with purified components, and/or blockade with specific Abs, it was found that soluble
EPCR
binds to proteinase-3 (PR3), a neutrophil granule proteinase. Furthermore, soluble
EPCR
binding to neutrophils was partially dependent on Mac-1 (CD11b/CD18), a beta(2) integrin involved in neutrophil signaling, and cell-cell adhesion events. PR3 is involved in multiple diverse processes, including hemopoietic proliferation, antibacterial activity, and autoimmune-mediated
vasculitis
. The observation that soluble
EPCR
binds to activated neutrophils via PR3 and a beta(2) integrin suggests that there may be a link between the protein C anticoagulant pathway and neutrophil functions.
...
PMID:The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. 1103 13
Elevated soluble thrombomodulin (sTM) levels are an accepted marker of endothelial damage. The physiological significance of plasma
endothelial protein C receptor
(sEPCR) levels is not known. To assess the relevance of this plasma protein in Wegener's granulomatosis (WG), sEPCR levels were measured in sera obtained from WG patients and related to disease activity, sTM levels, and other known markers of disease activity. In total, 129 sera (37 at active disease, 92 during follow-up) from 31 WG patients were tested. During active disease, eight (22%) and 17 (46%) out of 37 active sera had elevated levels of sEPCR and sTM, respectively (NS); sEPCR (r = 0.39; P = 0.02) and sTM (r = 0.53; P <0.01) levels correlated with disease activity (Birmingham
Vasculitis
Activity Score). Analysis of longitudinal sera revealed a significant increase in sEPCR (P = 0.01) and sTM (P = 0.04) levels prior to the moment of a relapse. Corrected for renal function, the increase in sEPCR remained significant (P =0.04) whereas sTM did not (NS). Levels of sEPCR correlated with sTM levels (r = 0.32; P < 0.001). Plasma levels of sEPCR respond to changes in the disease in patients with WG.
...
PMID:Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis. 1203 94
The presence of antiendothelial cell antibodies (AECAs) has been documented in Takayasu arteritis (TAK), a chronic granulomatous
vasculitis
. Here, we identify cell-surface autoantigens using an expression cloning system. A cDNA library of endothelial cells is retrovirally transfected into a rat myeloma cell line from which AECA-positive clones are sorted with flow cytometry. Four distinct AECA-positive clones are isolated, and
endothelial protein C receptor
(
EPCR
) and scavenger receptor class B type 1 (SR-BI) are identified as endothelial autoantigens. Autoantibodies against
EPCR
and SR-BI are detected in 34.6% and 36.5% of cases, respectively, with minimal overlap (3.8%). Autoantibodies against
EPCR
are also detected in ulcerative colitis, the frequent comorbidity of TAK. In mechanistic studies,
EPCR
and SR-BI function as negative regulators of endothelial activation.
EPCR
has also an effect on human T cells and impair Th17 differentiation. Autoantibodies against
EPCR
and SR-BI block the functions of their targets, thereby promoting pro-inflammatory phenotype.
...
PMID:Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. 3215 3